Mr. Isshiki was appointed NeuroDerm’s CEO in December 2022, after serving as NeuroDerm’s Chief Administrative Officer since 2020. With over 28 years of international business experience in the pharmaceutical industry, he has overseen the growth of global pharmaceutical companies and directed long-term strategic plans.

At his previous capacity as CAO, Mr. Isshiki was in charge on directing the company’s finance, HR, legal advisory and IP activities. Prior to this, Mr. Isshiki had served as the Company’s VP Planning & Coordination and oversaw post-merger integration on-site. He played, and continues to play, an important role in facilitating mutual understanding between two different cultures – that of a fast-paced, Israel-based R&D powerhouse, and that of a Japanese multinational corporation.

Mr. Isshiki has held a variety of research and managerial roles with increasing responsibilities since joining Tanabe Seiyaku in 1994. He had previously served as Senior Manager of the Corporate Strategic Planning Department of the Mitsubishi Tanabe Pharma Corporation where he was responsible for establishing the company’s medium-term business plan and managing R&D projects.

Mr. Isshiki received his MSc in Enzymology from Tohoku University in Japan.

Mr. David joined NeuroDerm in October 2019, bringing with him vast experience in device R&D and production scale-up. In his last role, Mr. David led the executive management of the Israeli site of West Pharmaceutical Services, a leading global company for the design and production of delivery systems for injectable drugs. Prior to his position at West, Mr. David acted as VP R&D at Oridion/Covidien/Medtronic, an international public company in the field of diagnostics.

Mr. David holds a BSc in Mechanical engineering from the Ben Gurion university, an MSc in Industrial Design from the Technion and an MBA in Technology and Startup Management from the Technion.

Ms. Yardeni has over 20 years of experience in the pharmaceutical industry in various capacities, gained within large pharmaceutical companies and CROs. She was previously with Teva Pharmaceutical Industries, most recently as VP, Head of Global Clinical Operation, where she was responsible for the operational execution of global development programs across all indications from Phase I to regulatory approval and commercialization. From 1999 to 2011, Ms. Yardeni held positions of increasing responsibility in the area of Biometrics at Teva, has led strategic planning and execution of outsourcing and off-shoring activities, as well as post-acquisition integration processes for various biometric functions.

Ms. Yardeni joined NeuroDerm in 2016 and served as COO until the Mitsubishi-Tanabe Pharma Company acquisition, when she was nominated to head the Clinical Development group. She received both her BA in Statistics and M.A. in Applied Statistics from Haifa University.

Mr. Gilbert joined NeuroDerm in 2018 to lead the newly-formed Pharmaceutical Development function. Bringing more than 26 years of experience in the pharmaceutical industry, he was previously VP CMC in Discovery & Product Development at Teva’s Global R&D. Prior to that he held roles of increasing responsibility at Teva, including VP Quality for Global R&D, contributing to the development of important and valuable new therapies such as Copaxone® and Azilect®.

Mr. Gilbert gained a BSc in Chemistry from the University of Manchester and holds an MSc and PhD in Materials from Cranfield University. He conducted post-doctoral research in Applied Chemistry at the Hebrew University of Jerusalem in Israel and is a member of the scientific advisory board of the Familial Dysautonomia Foundation.

Ms. Nahmany has over 20 years of experience in organizational transformation, joining NeuroDerm in 2016. Her work is focused on defining organizational strategy, implementing change management, and building leadership teams, with an emphasis on global development. Ms. Nahmany has advised companies in the pharmaceutical, biotech and communications sectors, including leading global companies such as Teva Pharmaceutical Industries. She has also served in various consultancy positions at PricewaterhouseCoopers and McKinsey, and was COO of White Water, focused on smart water network management software.
Ms. Nahmany holds an MSc in Management and a diploma in Group Dynamics from Tel Aviv University.

Ms. Baer joined NeuroDerm in 2021 as VP Quality. In this capacity she oversees all quality activities at NeuroDerm, covering preclinical, clinical, manufacturing & operations stages, as well as testing and release of drug-device combination products.
Karin has more than 30 years’ experience in senior Quality positions in the pharmaceutical industry. In her last role, Karin served as Head of Corporate QA at Boehringer Ingelheim based in Germany, where she worked to improve quality and compliance processes. Prior to this position she had served in various quality leadership positions at Teva Pharmaceutical Industries, most recently as VP Regional Head Quality Operations, where she advanced global projects while supervising over 1,000 Quality employees.
Karin holds a BSc in Chemistry and Biochemistry from the Hebrew University of Jerusalem.

Ms. Shmueli-Dayan joined NeuroDerm in 2020 as VP Finance. In this capacity, Ms. Shmueli-Dayan is responsible for all financial aspects, including finance operations, strategic forecasting and planning, as well as overseeing procurement processes and IT operations within the company.

Ms. Shmueli-Dayan is highly experienced in establishing and leading global finance organizations and leading strategic and transformational initiatives. Prior to joining NeuroDerm, she had served as VP Finance at Avgol Nonwovens, a manufacturer of non-woven fabric solutions, as well as serving two decades in various finance-related capacities at Teva Pharmaceutical Industries. Her most recent roles at Teva were CFO of Global Operations and SVP and CFO of Global Functions, where she oversaw the financial operations for Business Development and Global Functions within the company.

Ms. Shmueli-Dayan holds a BA with majors in Economics and Business Management, as well as an MBA with specialties in Finance and Marketing, both from the Hebrew University of Jerusalem.

Mr. Ekbali has over 19 years of experience in various operational management positions in the pharmaceutical industry. As the former General Manager of the Jerusalem production site at Teva Pharmaceutical Industries, he was responsible for mass production and packaging operations in excess of US$70 million annually, and led over 500 employees to exceed operational targets.

Prior to his role as General Manager, Mr. Ekbali served in various positions at Teva, as Head of Operations, Director of Strategic Planning and Head of Supply Chain in regional and global positions. He has vast experience in complex project management in multi-cultural and multi-disciplinary environments.

Mr. Ekbali holds a BSc in Industrial Engineering and an MBA in Finance and Strategy, both from Tel-Aviv University.

Ms. Mesika joined NeuroDerm in 2016. She has more than 25 years of R&D and regulatory experience in the pharmaceutical industry working for both medium and large pharmaceutical companies. During her six-year tenure at Teva Pharmaceutical Industries, Ms. Mesika was the Global RA leader of biosimilar products in Global R&D and Head of Regulatory Affairs for Specialty Products in Growth Markets region. She was responsible for setting the regulatory strategy for development and registration of innovative drugs, biologics and combination products in various therapeutic areas, including CNS, Pain, Oncology, and Respiratory.
Ms. Mesika holds a BSc in Biology from the Hebrew University of Jerusalem.